Janux Therapeutics highlighted forward-looking clinical milestones for its TRACTr oncology programs and detailed a new global collaboration with Bristol Myers Squibb to develop a tumor-activated therapeutic for solid tumors.
Written By: PharmacallyMedical News Desk
Janux Therapeutics has outlined upcoming clinical milestones for its TRACTr oncology programs expected in 2026 while also detailing a new solid tumor collaboration with Bristol Myers Squibb, according to updates released with its 2025 financial results.
Pipeline Progress
Janux expects continued clinical advancement of its tumor-activated TRACTr platform programs, including JANX007, JANX008, and JANX011.
The company is currently enrolling a Phase 1b cohort of JANX007 in taxane-naive metastatic castration-resistant prostate cancer (mCRPC). Ongoing development plans include optimization of monotherapy dosing as well as evaluation in combination with darolutamide, an androgen receptor pathway inhibitor, to further characterize safety and clinical activity in this patient population. Additional expansion cohorts are also evaluating JANX007 monotherapy in PARP inhibitor-refractory mCRPC.
Meanwhile, JANX008 continues to advance in a Phase 1 clinical study in defined solid tumor populations, with expansion cohorts designed to further characterize safety and anti-tumor activity across selected tumor settings.
Janux has also initiated a Phase 1 study of JANX011 in healthy volunteers, representing the clinical entry of another candidate built on its tumor-activated technology platform.
Looking ahead, the company expects to provide additional clinical updates for JANX007 and JANX008 during 2026, potentially at future medical meetings. Janux also anticipates sharing an initial clinical update from the Phase 1 study of JANX011 by the end of 2026.
Bristol Myers Squibb Collaboration
Separately, Janux recently entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen.
Under the agreement, Janux will lead preclinical development through investigational new drug (IND) submission, after which Bristol Myers Squibb will assume responsibility for clinical development and global commercialization.
The partnership includes $50 million in upfront and near-term milestone payments, with the potential for approximately $800 million in additional development, regulatory, and commercial milestone payments, along with tiered royalties on global product sales if the therapy is successfully commercialized.
Janux has also strengthened its clinical leadership with the appointment of William Go, M.D., Ph.D. as Chief Medical Officer, as the company prepares to advance multiple programs through early clinical development and toward upcoming clinical milestones.
Reference
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights, 26 March 2026, Janux – Investor Relations – Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
